Carregant...
ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies
ERBB2/HER2 has long been recognized as an oncogenic driver in some breast and gastro-esophageal cancers, in which amplification of this gene confers sensitivity to treatment with ERBB2 directed agents. More recently, somatic mutations in ERBB2 have been reported in 1–2% of patients with lung adenoca...
Guardat en:
| Publicat a: | J Thorac Oncol |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5402884/ https://ncbi.nlm.nih.gov/pubmed/28167203 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2017.01.023 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|